Table 2 Compliance with study medication (total course duration up to 14 days)
Liquid Kaloba® (n = 27) | Liquid placebo (n = 25) | Tablet Kaloba® (n = 16) | Tablet placebo (n = 20) | All participants | |
|---|---|---|---|---|---|
Stopped in week 1 | 4/27 (14.8%) | 5/25 (20.0%) | 3/16 (18.8%) | 2/20 (10.0%) | 14/88 (15.9%) |
Stopped in week 2 | 14/24 (58.3%) | 14/20 (70.0%) | 9/16 (56.3%) | 15/21 (71.4%) | 52/81 (64.2%) |
Stopped in week 1 but still experienced moderately bad symptoms | 2/17 (11.8%) | 0/16 (0.0%) | 1/9 (11.1%) | 1/11 (9.1%) | 4/53 (7.5%) |
Stopped in week 2 but still experienced moderately bad symptoms | 5/9 (55.6%) | 6/9 (66.7%) | 0/2 (0.0%) | 4/7 (57.1%) | 15/27 (55.6%) |
Stopped in week 1 but had not recovered from all symptoms | 2/20 (10.0%) | 2/20 (10.0%) | 1/14 (7.1%) | 2/17 (11.8%) | 7/71 (9.9%) |
Stopped in week 2 but had not recovered from all symptoms | 5/10 (50.0%) | 6/10 (60.0%) | 1/8 (12.5%) | 6/10 (60.0%) | 18/38 (47.4%) |
Median (IQR) doses taken in week 1 | 20 (17,21) | 18.5 (17,20) | 19 (18,21) | 19 (18, 21) | 19 (18,21) |
➙Morning | 6 (6,7) | 6 (5,6) | 6 (6,7) | 6 (6,7) | 6 (6,7) |
➙Afternoon | 7 (5,7) | 6 (5,7) | 7 (6,7) | 6.5 (5,7) | 7 (5,7) |
➙Evening | 7 (7,7) | 7 (6,7) | 7 (6,7) | 7 (6,7) | 7 (6,7) |